ATB Stock Overview
Antibiotice S.A. develops and produces generic drugs in Romania.
Price History & Performance
|Historical stock prices|
|Current Share Price||RON0.58|
|52 Week High||RON0.59|
|52 Week Low||RON0.48|
|1 Month Change||1.41%|
|3 Month Change||2.49%|
|1 Year Change||16.60%|
|3 Year Change||17.79%|
|5 Year Change||11.63%|
|Change since IPO||599.13%|
Recent News & Updates
Is Antibiotice (BVB:ATB) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|ATB||RO Pharmaceuticals||RO Market|
Return vs Industry: ATB underperformed the RO Pharmaceuticals industry which returned 19.3% over the past year.
Return vs Market: ATB underperformed the RO Market which returned 33.8% over the past year.
|ATB Average Weekly Movement||1.6%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||3.9%|
|10% most volatile stocks in RO Market||6.3%|
|10% least volatile stocks in RO Market||2.1%|
Stable Share Price: ATB is less volatile than 75% of RO stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: ATB's weekly volatility (2%) has been stable over the past year.
About the Company
Antibiotice S.A. develops and produces generic drugs in Romania. The company’s portfolio of products comprises approximately 150 medicines for human use in 12 therapeutic classes, as well as medicines for veterinary use. It offers sterile injectable powders, capsules, tablets, ointments, gels, creams, suppositories, and active substances.
Antibiotice Fundamentals Summary
|ATB fundamental statistics|
Is ATB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATB income statement (TTM)|
|Cost of Revenue||RON171.30m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.04|
|Net Profit Margin||6.75%|
How did ATB perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is Antibiotice undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ATB (RON0.58) is trading above our estimate of fair value (RON0.11)
Significantly Below Fair Value: ATB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ATB is good value based on its PE Ratio (14.6x) compared to the European Pharmaceuticals industry average (26.7x).
PE vs Market: ATB is poor value based on its PE Ratio (14.6x) compared to the RO market (12.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATB is good value based on its PB Ratio (0.7x) compared to the XE Pharmaceuticals industry average (3.1x).
How is Antibiotice forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Antibiotice has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Antibiotice performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATB has high quality earnings.
Growing Profit Margin: ATB's current net profit margins (6.8%) are lower than last year (7.6%).
Past Earnings Growth Analysis
Earnings Trend: ATB's earnings have declined by 3.5% per year over the past 5 years.
Accelerating Growth: ATB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ATB had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.6%).
Return on Equity
High ROE: ATB's Return on Equity (4.5%) is considered low.
How is Antibiotice's financial position?
Financial Position Analysis
Short Term Liabilities: ATB's short term assets (RON342.5M) exceed its short term liabilities (RON156.7M).
Long Term Liabilities: ATB's short term assets (RON342.5M) exceed its long term liabilities (RON94.5M).
Debt to Equity History and Analysis
Debt Level: ATB's net debt to equity ratio (23.8%) is considered satisfactory.
Reducing Debt: ATB's debt to equity ratio has increased from 13.9% to 24.5% over the past 5 years.
Debt Coverage: ATB's debt is well covered by operating cash flow (41.9%).
Interest Coverage: ATB's interest payments on its debt are well covered by EBIT (9.1x coverage).
What is Antibiotice current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ATB's dividend (0.57%) isn’t notable compared to the bottom 25% of dividend payers in the RO market (2.82%).
High Dividend: ATB's dividend (0.57%) is low compared to the top 25% of dividend payers in the RO market (5.42%).
Stability and Growth of Payments
Stable Dividend: ATB is not paying a notable dividend for the RO market, therefore no need to check if payments are stable.
Growing Dividend: ATB is not paying a notable dividend for the RO market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ATB is not paying a notable dividend for the RO market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATB's dividend in 3 years as they are not forecast to pay a notable one for the RO market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ioan Nani (62 yo)
Mr. Ioan Nani serves as General Manager and Non-Independent Director at Antibiotice S.A. since 2009. He served as Non-Independent Vice President of Board at Antibiotice S.A., since October 2019. He served...
Experienced Management: ATB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: ATB's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Antibiotice S.A.'s employee growth, exchange listings and data sources
- Name: Antibiotice S.A.
- Ticker: ATB
- Exchange: BVB
- Founded: 1955
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: RON386.691m
- Shares outstanding: 671.34m
- Website: https://www.antibiotice.ro
Number of Employees
- Antibiotice S.A.
- 1 Valea Lupului Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/24 22:44|
|End of Day Share Price||2021/11/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.